Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1977 3
1978 4
1982 1
1983 2
1984 3
1985 2
1986 3
1987 18
1988 31
1989 42
1990 52
1991 81
1992 81
1993 86
1994 83
1995 99
1996 104
1997 103
1998 167
1999 164
2000 215
2001 232
2002 265
2003 232
2004 279
2005 262
2006 264
2007 307
2008 359
2009 401
2010 396
2011 472
2012 554
2013 659
2014 1096
2015 1515
2016 1999
2017 2464
2018 2920
2019 3818
2020 5597
2021 7470
2022 7916
2023 8764
2024 3069

Text availability

Article attribute

Article type

Publication date

Search Results

46,346 results

Results by year

Filters applied: . Clear all
Page 1
Immune checkpoint therapy-current perspectives and future directions.
Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Sharma P, et al. Cell. 2023 Apr 13;186(8):1652-1669. doi: 10.1016/j.cell.2023.03.006. Cell. 2023. PMID: 37059068 Review.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Agarwal N, et al. Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4. Lancet. 2023. PMID: 37285865 Clinical Trial.
Prostate cancer.
Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Sandhu S, et al. Lancet. 2021 Sep 18;398(10305):1075-1090. doi: 10.1016/S0140-6736(21)00950-8. Epub 2021 Aug 6. Lancet. 2021. PMID: 34370973 Review.
Similarly, the emergence of more sensitive imaging methods has improved diagnostic and staging accuracy and refined surveillance strategies. These advances have introduced personalised therapeutics to clinical practice, with treatments targeting genomic alterations in DNA …
Similarly, the emergence of more sensitive imaging methods has improved diagnostic and staging accuracy and refined surveillance strategies. …
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. Horwitz S, et al. Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16. Ann Oncol. 2022. PMID: 34921960 Free PMC article. Clinical Trial.
Immune checkpoint inhibitors in melanoma.
Carlino MS, Larkin J, Long GV. Carlino MS, et al. Lancet. 2021 Sep 11;398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X. Lancet. 2021. PMID: 34509219 Review.
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. DiNardo CD, et al. J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27. J Clin Oncol. 2021. PMID: 34043428 Free PMC article. Clinical Trial.
Relapsed or refractory AML (R/R-AML) remains a particularly adverse population necessitating improved therapeutic options. This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined wi …
Relapsed or refractory AML (R/R-AML) remains a particularly adverse population necessitating improved therapeutic options. This phase …
46,346 results
You have reached the last available page of results. Please see the User Guide for more information.